A breast surgeon explains why patients should raise lymphedema with their care team at the start of treatment, and how early detection can make it reversible.
|Articles|July 10, 2015
Kara Maxwell Explains Breast Cancer Clinical Trials
Author(s)Kara Maxwell
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, explains how a breast cancer clinical trial works.
Advertisement
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, explains how a breast cancer clinical trial works.
Advertisement
Related to this article
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.
Dr. Matteo Lambertini explains how Lynkuet reduced hot flashes in people on endocrine therapy for breast cancer, no matter when their treatment began.
A woman treated for DCIS breast cancer with a double mastectomy shares why her smoother recovery left her with survivor guilt and feeling like an impostor.
Dr. Sara Hurvitz explains why giving Enhertu before surgery didn't change care for HER2-low, HR-positive early breast cancer, and what patients should know.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
3
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
4
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
5